Lexicon Pharmaceuticals | LXRX - Operating Expenses


Lexicon Pharmaceuticals reported $20.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 10.46B 1.15B Jun/2026
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Illumina USD 899M 47M Jun/2026
Insmed USD 526.79M 20.55M Jun/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 17.83B 388M Jun/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD 110.21M 690K Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Moderna USD 960M 817M Jun/2026
Novartis USD 10.2B 912M Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Thermo Fisher Scientific USD 9.81B 716M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025